Patents by Inventor Janet Blanks

Janet Blanks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170143653
    Abstract: Compositions and methods described herein are based on the use of the drug sulindac, a non steroidal anti-inflammatory drug (NSAID), for protecting retinal pigment epithelial cells against oxidative stress which is a major component of macular degeneration. Described herein is a new use for sulindac.
    Type: Application
    Filed: February 2, 2017
    Publication date: May 25, 2017
    Inventors: Howard M. Prentice, Herbert Weissbach, Janet Blanks
  • Publication number: 20120295979
    Abstract: Compositions and methods described herein are based on the use of the drug sulindac, a non steroidal anti-inflammatory drug (NSAID), for protecting retinal pigment epithelial cells against oxidative stress which is a major component of macular degeneration. Described herein is a new use for sulindac.
    Type: Application
    Filed: May 3, 2012
    Publication date: November 22, 2012
    Applicant: Florida Atlantic University
    Inventors: Howard M. PRENTICE, Herbert Weissbach, Janet Blanks
  • Publication number: 20050261234
    Abstract: Compositions and methods for reducing neovascularization. Purified nucleic acid constructs and vectors encoding an anti-angiogenic protein operably linked to a GFAP promoter. Vectors can include at least one hypoxia regulated element, enhancer element and silencer element. Gene therapy methods for reducing, delaying or preventing neovascularization based on the nucleic acid constructs and vectors.
    Type: Application
    Filed: April 22, 2005
    Publication date: November 24, 2005
    Applicant: Florida Atlantic University
    Inventors: C. Dorey, Janet Blanks, Howard Prentice